NEWS 2017-09-21T19:47:34+00:00
  • Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants
    by Carolina Henriques on October 20, 2017 at 4:05 pm

    This post was originally published on this site Three American scientists have received $1.3 million from the Alliance for Cancer Gene Therapy to investigate whether immunotherapy and gene therapy can combat three of the most life-threatening forms of cancer: ovarian, brain and bone cancer. The three are Drs. Daniel Powell Jr. of the University of Pennsylvania’s Perelman […] The post Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants appeared first on BioNewsFeeds. […]

  • Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors
    by admin on October 18, 2017 at 6:54 pm

    This post was originally published on this site The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. The trial will assess the safety, tolerability, and effectiveness of the new treatment in participants recruited at […] The post Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors appeared first on BioNewsFeeds. […]

  • First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
    by admin on October 16, 2017 at 6:21 pm

    This post was originally published on this site The pharmaceutical development company NanOlogy has enrolled the first participant in its Phase 2 trial evaluating the safety and effectiveness of NanoPac, a new delivery method for the anti-cancer treatment paclitaxel in ovarian cancer patients. “If successful, we may add to the newer treatment options that are […] The post First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery appeared first on BioNewsFeeds. […]

  • Swansea University Researchers Win Award for Innovative Ovarian Cancer Diagnostic Test
    by Carolina Henriques on October 13, 2017 at 6:33 pm

    This post was originally published on this site An international research team at Swansea University Medical School and the university’s Centre for NanoHealth in the United Kingdom has received an international award for developing a graphene biosensor-based diagnostic test for ovarian cancer that offers quicker and more accurate results in a less expensive and portable way. […] The post Swansea University Researchers Win Award for Innovative Ovarian Cancer Diagnostic Test appeared first on BioNewsFeeds. […]

  • Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy
    by Magdalena Kegel on October 11, 2017 at 3:11 pm

    This post was originally published on this site Clovis Oncology house to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, Colorado, has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and […] The post Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy appeared first on BioNewsFeeds. […]

  • After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients
    by admin on October 9, 2017 at 5:19 pm

    This post was originally published on this site Mateon Therapeutics announced that it is immediately ending the FOCUS trial of CA4P to treat platinum-resistant ovarian cancer, based on disappointing interim results. The results showed that CA4P (fosbretabulin) did not significantly improve progression-free survival in patients receiving CA4P plus standard of care with Avastin (bevacizumab) and chemotherapy. FOCUS […] The post After Disappointing Results, Mateon to End FOCUS Trial for CA4P in Ovarian Cancer Patients appeared first on BioNewsFeeds. […]

  • TESARO Partners with Olympian Shannon Miller to Expand Program for Ovarian Cancer Community
    by Carolina Henriques on October 6, 2017 at 5:12 pm

    This post was originally published on this site TESARO, a biopharmaceutical company working on new cancer therapies, has launched a number of new resources and services for women living with ovarian cancer, as part of the expansion of its ‘Our Way Forward’ platform. The program was launched earlier this year featuring the results of a national […] The post TESARO Partners with Olympian Shannon Miller to Expand Program for Ovarian Cancer Community appeared first on BioNewsFeeds. […]

  • Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients
    by admin on October 4, 2017 at 2:54 pm

    This post was originally published on this site All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who never had been treated. Among them, 100 percent had at least stable disease, and 86 percent saw […] The post Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients appeared first on BioNewsFeeds. […]

  • Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference
    by Magdalena Kegel on October 2, 2017 at 5:00 pm

    This post was originally published on this site Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 Meeting in Madrid. It was one of a host of presentations the company delivered on Zejula (niraparib) and […] The post Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference appeared first on BioNewsFeeds. […]

  • Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer
    by admin on September 29, 2017 at 5:20 pm

    This post was originally published on this site Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. The trial, which included 23 evaluable patients with either […] The post Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer appeared first on BioNewsFeeds. […]